KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Audioeye (AEYE) Asset Writedowns and Impairment (2017 - 2025)

Historic Asset Writedowns and Impairment for Audioeye (AEYE) over the last 8 years, with Q3 2025 value amounting to $93000.0.

  • Audioeye's Asset Writedowns and Impairment rose 13846.15% to $93000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $468000.0, marking a year-over-year increase of 18363.64%. This contributed to the annual value of $236000.0 for FY2024, which is 42.55% up from last year.
  • Audioeye's Asset Writedowns and Impairment amounted to $93000.0 in Q3 2025, which was up 13846.15% from $149000.0 recorded in Q2 2025.
  • In the past 5 years, Audioeye's Asset Writedowns and Impairment ranged from a high of $149000.0 in Q2 2025 and a low of -$38000.0 during Q4 2021
  • In the last 5 years, Audioeye's Asset Writedowns and Impairment had a median value of $75000.0 in 2022 and averaged $71222.2.
  • In the last 5 years, Audioeye's Asset Writedowns and Impairment plummeted by 30000.0% in 2021 and then surged by 47333.33% in 2024.
  • Over the past 5 years, Audioeye's Asset Writedowns and Impairment (Quarter) stood at -$38000.0 in 2021, then surged by 415.79% to $120000.0 in 2022, then tumbled by 87.5% to $15000.0 in 2023, then surged by 473.33% to $86000.0 in 2024, then increased by 8.14% to $93000.0 in 2025.
  • Its Asset Writedowns and Impairment was $93000.0 in Q3 2025, compared to $149000.0 in Q2 2025 and $140000.0 in Q1 2025.